Svetlana Ten
Pediatric Endocrinology · Staten Island, NYNPI 1316932015
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $82,320 of the $101,004 with a category attached, or 81.5%. 28 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 51.5% of the total. Among pediatric endocrinology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 268 payments — averaging $376.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$52K
- Rhythm Pharmaceuticals, Inc.$25K
- Biomarin Pharmaceutical Inc.$10K
- Insulet Corporation$5K
- Mannkind Corporation$3K
- Pfizer$2K
- plus $3K from 22 others
Across 579 payments — averaging $1266.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rhythm Pharmaceuticals, Inc.$715K
- Sanofi US Services Inc.$7K
- Amryt Pharma Holdings Ltd$6K
- Novo Nordisk Health Care AG$3K
- Chiesi USA, Inc.$1K
- Merck$92
What the payments were for
- Speaking & faculty fees$82,32082%
- Travel & lodging$10,71911%
- Food & beverage$7,8908%
- Education$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 44 | $52,017 |
| Rhythm Pharmaceuticals, Inc. | 45 | $25,391 |
| Biomarin Pharmaceutical Inc. | 12 | $10,012 |
| Insulet Corporation | 29 | $5,330 |
| Mannkind Corporation | 6 | $2,850 |
| Pfizer | 14 | $2,265 |
| Novo Nordisk | 31 | $815 |
| AbbVie | 23 | $603 |
| Abbott | 10 | $263 |
| Ascendis Pharma Endocrinology Inc | 10 | $217 |
| AstraZeneca | 6 | $216 |
| Medtronic(2 entities) | 3 | $136 |
| BETA Bionics, Inc. | 2 | $121 |
| Tolmar, Inc. | 1 | $115 |
| Dexcom, Inc. | 5 | $101 |
| Xeris Pharmaceuticals, Inc. | 4 | $95 |
| Ipsen Biopharmaceuticals, Inc | 4 | $90 |
| Azurity Pharmaceuticals, Inc. | 4 | $73 |
| Ferring Pharmaceuticals Inc. | 3 | $66 |
| Zealand Pharma US, Inc. | 2 | $39 |
| Amneal Pharmaceuticals LLC | 2 | $33 |
| Tandem Diabetes Care, Inc. | 2 | $29 |
| Lilly USA, LLC | 1 | $25 |
| Amphastar Pharmaceuticals, Inc. | 1 | $24 |
| Chiesi USA, Inc. | 1 | $23 |
| Pharming Healthcare, Inc. | 1 | $21 |
| Amryt Pharma Holdings Ltd | 1 | $18 |
| IBSA Pharma Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$46,869
- Imcivree$22,381
- VOXZOGO 1.2mg$9,372
- Omnipod$5,025
- AFREZZA$2,671
- NGENLA$1,800
- iLet Bionic Pancreas$303
- Synthroid$123
- Sogroya$120
- Strensiq$115
- FENSOLVI$115
- iLet Insulin Infusion Kit Inset$101
- iLet Insulin Infusion Kit Contact Detach$101
How this compares
$101,004 in reported general payments places this provider in the 95th percentile of 138 pediatric endocrinology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 24 | $24,707 |
| HumalogInsulin Lispro | 11 | $2,878 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Humalog | $25 | $27,58435 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 138 pediatric endocrinology providers in New York.
Other pediatric endocrinology in Staten Island
- Ishita KharodeStaten Island$1K
- Paul SaengerMineola$180K
- Alicia RomanoSleepy Hollow$157K
- Robert RapaportNew York$98K
- Moris AnguloMineola$73K
- Jill BrodskyPoughkeepsie$45K
- Jorge Mejia-CorlettoNorth Babylon$44K
- Angela VerardoBronx$38K
- Christopher RomeroNew York$35K
- Robert LevineMineola$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.